New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
- PMID: 30637567
- PMCID: PMC6330561
- DOI: 10.1007/s11883-019-0762-1
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
Abstract
Purpose of review: Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk. Genetic and epidemiologic studies have shown that elevated fasting TG levels are associated with incident cardiovascular events. At effective doses, omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels but may have additional atheroprotective properties compared to other TG-lowering therapies such as niacin and fibrates. The purpose of this review is to evaluate mechanisms related to the potential benefits of omega-3 fatty acids in atherothrombotic disease.
Recent findings: Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day). A large randomized trial with a prescription EPA-only formulation was shown to reduce a composite of cardiovascular events by 25% in statin-treated patients with established cardiovascular disease or diabetes and other CV risk factors. EPA and DHA have distinct tissue distributions as well as disparate effects on membrane structure and lipid dynamics, rates of lipid oxidation, and signal transduction pathways. Compared to other TG-lowering therapies, EPA has been found to inhibit cholesterol crystal formation, inflammation, and oxidative modification of atherogenic lipoprotein particles. The anti-inflammatory and endothelial benefits of EPA are enhanced in combination with a statin. Omega-3 fatty acids like EPA only at a pharmacologic dose reduce fasting TG and interfere with mechanisms of atherosclerosis that results in reduced cardiovascular events. Additional mechanistic trials will provide further insights into their role in reducing cardiovascular risk in subjects with well-managed LDL-C but elevated TG levels.
Keywords: Atherosclerosis; Cholesterol; Eicosapentaenoic; Lipoproteins; Omega-3 fatty acids; Triglycerides.
Conflict of interest statement
Conflict of Interest
R. Preston Mason has received grant/research support from Amarin Pharma Inc., Pfizer Inc., Amgen Inc., ARCA Biopharma, and Novartis AG. Dr. Mason is also a paid speaker and consultant for Amarin Pharma Inc., Pfizer Inc., and Novartis AG.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6330561/bin/11883_2019_762_Fig1_HTML.gif)
Similar articles
-
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.Curr Atheroscler Rep. 2023 Jan;25(1):1-17. doi: 10.1007/s11883-022-01075-x. Epub 2022 Dec 29. Curr Atheroscler Rep. 2023. PMID: 36580204 Free PMC article. Review.
-
Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.Curr Atheroscler Rep. 2020 Oct 3;22(12):74. doi: 10.1007/s11883-020-00893-1. Curr Atheroscler Rep. 2020. PMID: 33009961 Review.
-
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7. Endocr Pract. 2017. PMID: 27819772 Review.
-
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.Postgrad Med. 2015;127(8):869-73. doi: 10.1080/00325481.2015.1100086. Epub 2015 Oct 9. Postgrad Med. 2015. PMID: 26453247
-
Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.Am J Ther. 2016 May-Jun;23(3):e905-10. doi: 10.1097/MJT.0000000000000165. Am J Ther. 2016. PMID: 25828517 Review.
Cited by
-
Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships.Research (Wash D C). 2024 Aug 20;7:0447. doi: 10.34133/research.0447. eCollection 2024. Research (Wash D C). 2024. PMID: 39165638 Free PMC article.
-
Lipid-Derived Biomarkers as Therapeutic Targets for Chronic Coronary Syndrome and Ischemic Stroke: An Updated Narrative Review.Medicina (Kaunas). 2024 Mar 29;60(4):561. doi: 10.3390/medicina60040561. Medicina (Kaunas). 2024. PMID: 38674207 Free PMC article. Review.
-
Differentiating EPA from EPA/DHA in cardiovascular risk reduction.Am Heart J Plus. 2022 May 28;17:100148. doi: 10.1016/j.ahjo.2022.100148. eCollection 2022 May. Am Heart J Plus. 2022. PMID: 38559888 Free PMC article. Review.
-
Biomarker-based validation of a food frequency questionnaire for the assessment of omega-3 fatty acid status in a healthy Iranian population.Sci Rep. 2023 Sep 8;13(1):14813. doi: 10.1038/s41598-023-41623-2. Sci Rep. 2023. PMID: 37684272 Free PMC article.
-
A comprehensive toxicological analysis of trans-fatty acids (TFAs) reveals a pro-apoptotic action specific to industrial TFAs counteracted by polyunsaturated FAs.Sci Rep. 2023 Apr 11;13(1):5883. doi: 10.1038/s41598-023-32083-9. Sci Rep. 2023. PMID: 37041254 Free PMC article.
References
-
- Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–1639. doi: 10.1016/S0140-6736(10)60545-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous